Africa’s path to pharmaceutical independence: breaking free from medical dependency

Why Africa Must Prioritize Pharmaceutical Sovereignty

For decades, African nations have relied heavily on imported medications to meet the healthcare needs of their populations. This dependence is not just an economic burden but a critical vulnerability, as evidenced by recent global supply chain disruptions. The time has come for Africa to chart its own course toward pharmaceutical self-sufficiency.

Currently, fewer than five African countries operate manufacturing facilities capable of exporting pharmaceutical products beyond their borders. This stark reality means the continent still imports 94% of its medicines, spending over $18 billion annually—a figure projected to exceed $30 billion by 2030 according to industry forecasts. The consequences extend far beyond economics: public health systems face chronic shortages, with more than 70% of public health facilities reporting critical stockouts at least once per quarter.

During the Covid-19 pandemic, these vulnerabilities became painfully evident. Essential drugs like amoxicillin, insulin, and anesthetics faced severe shortages, while life-saving treatments such as cancer medications remained inaccessible to millions. The human cost? Delayed treatments, inflated prices during shortages, and crippled public health programs. Yet Africa possesses untapped potential to transform this crisis into opportunity.

Unlocking Africa’s Pharmaceutical Potential

Africa’s path to pharmaceutical independence rests on four key pillars:

• A booming market: The continent’s pharmaceutical sector could reach $70 billion by 2030, creating unprecedented demand for locally produced medicines.
• Rich biodiversity: Over 5,400 medicinal plants have been documented across Africa, with several already integrated into official therapeutic protocols.
• Regulatory momentum: The African Medicines Agency (AMA), now ratified by 27 countries, is harmonizing pharmaceutical standards across the continent.
• Political will: Visionary nations like Burkina Faso, Rwanda, Egypt, Morocco, Senegal, and South Africa have launched ambitious local production initiatives.

Lessons from Failed Industrialization Attempts

Many African countries have attempted to establish pharmaceutical industries by importing foreign equipment without simultaneously developing local expertise, technical know-how, or industrial capacity. This approach has consistently led to:

• Higher production costs than imported medications
• Persistent dependence on foreign raw materials and technologies
• Failure to achieve true pharmaceutical sovereignty

The solution lies in a strategic, step-by-step approach that prioritizes:

• Building local technical expertise
• Developing indigenous industrial capacity
• Creating sustainable supply chains for active pharmaceutical ingredients
• Establishing quality control systems aligned with international standards

Pharmaceutical industrialization in Africa demands rigorous methodology, long-term vision, and unwavering commitment—qualities that have historically been in short supply across the continent’s development efforts.

A Clear Roadmap for 2045

To achieve pharmaceutical sovereignty by 2045, African leaders must adopt a comprehensive strategy that:

• Prioritizes essential medicines: Focus first on producing high-demand, life-saving medications where local production offers clear advantages.
• Leverages regional collaboration: Pool resources and expertise through initiatives like the AMA to create economies of scale.
• Invests in human capital: Develop training programs for pharmacists, chemists, and engineers to build the technical workforce needed for a modern pharmaceutical industry.
• Strengthens regulatory frameworks: Ensure all production meets international quality standards while adapting to African realities.

The choice is stark: Africa can continue down the path of dependence, or it can seize this moment to build an industry that produces medicines for Africans, by Africans. The latter path requires bold leadership, sustained investment, and a willingness to learn from both successes and failures in other regions.

Ultimately, pharmaceutical sovereignty is about more than economic independence—it’s about reclaiming control over the health and wellbeing of 1.4 billion people. By producing medicines locally, Africa can ensure consistent supply, competitive pricing, and rapid response to health crises. In doing so, it won’t just transform its healthcare system—it will position itself to become a global leader in pharmaceutical innovation.

Dr. Arnaud Kaboré
Pharmacist and Health Sector Executive